Astria Therapeutics, (id:6608 ATXS)
9.65 USD
Opening hours: 09:30 - 16:00 (Eastern Standard Time: 11/23/2024 8:24:43 PM)
Exchange closed, opens in 1 day 13 hours
About Astria Therapeutics,
Market Capitalization 544.59M
Astria Therapeutics, Inc., a biopharmaceutical company, focuses on the discovery, development, and commercialization of therapeutics for allergic and immunological diseases in the United States. Its lead product candidate is STAR-0215, a monoclonal antibody inhibitor of plasma kallikrein, which is in Phase 1b/2 clinical trials for the treatment of hereditary angioedema. The company is also developing STAR-0310, a monoclonal antibody OX40 antagonist that is in preclinical development for the treatment of atopic dermatitis, an immune disorder associated with loss of skin barrier function and itching. The company was formerly known as Catabasis Pharmaceuticals, Inc. and changed its name to Astria Therapeutics, Inc. in September 2021. Astria Therapeutics, Inc. was incorporated in 2008 and is headquartered in Boston, Massachusetts.
| Headquarters (address) |
75 State Street Boston 02109 MA United States |
| Phone | 617 349 1971 |
| Website | https://www.astriatx.com |
| Employees | 59 |
| Sector | Healthcare |
| Industry | Biotechnology |
| Ticker | ATXS |
| Exchange | NASDAQ Stock Exchange |
| Currency | USD |
| 52 week range | 4.43 - 16.90 |
| Market Capitalization | 544.59M |
| P/E trailing | -3.99 |
| P/E forward | -5.45 |
| Price/Book | 2.27 |
| Beta | 0.714 |
| EPS | -2.18 |
| EPS United States (ID:6, base:3403) | 24.22 |